The 64th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine / The 44th Annual Meeting of the Japanese Society of Nuclear Medicine Technology

Greeting / The 64th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine

会長

The 64th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine
chair Jun Hashimoto
(Tokai University School of Medicine)

I have the honor of organizing the 64th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine (JSNM). The 64th Annual Scientific Meeting of the JSNM will be held jointly with the 44th Annual Meeting of the Japanese Society of Nuclear Medicine Technology chaired by Kazuaki Mori sensei, from November 7–9, 2024 in Yokohama at the PACIFICO Yokohama Conference Center and Exhibition Hall A.

The general theme of the Annual Scientific Meeting is “Nuclear Medicine – Creation and Communication.” It signifies people working in a range of different fields joining hands to create new knowledge through nuclear medicine, and the poster design features the Air Cabin ropeway that spans the city of Yokohama.

I feel that in recent years nuclear medicine has been moving toward a massive transformation that will occur in the near future. The other day, I heard the news that a disease-modifying drug for Alzheimer’s dementia has been approved in Japan. Health insurance coverage for amyloid PET, which is the dearest wish of nuclear medicine professionals, is also finally becoming a reality, and there are high expectations for future dementia care by means of PET including tau imaging. The high resolution and excellent diagnostic performance of 68Ga-PSMA and FAPI, tumor imaging agents used in PET, and 18F-flurpiridaz, a myocardial perfusion imaging agent, are amazing, and nuclear medical treatment for conditions such as neuroendocrine tumors and prostate cancer is also poised to make great strides in future. New developments in disease concepts and advances in treatment methods are also focusing attention in new possibilities for existing investigations, and with the diagnosis of cardiac amyloidosis by pyrophosphate scintigraphy, the diagnosis of triglyceride deposit cardiomyovasculopathy (TGCV) by 123I-BMIPP, and the use of myocardial perfusion SPECT to monitor myocardial regeneration therapy with iPS cells, there is no lack of topics in this area. I intend to put together a program that will enable all those who attend to experience these new currents in nuclear medicine.

The JSNM was established in November 1964, and the holding of this Annual Scientific Meeting in November 2024 will mark its 60th anniversary. Strange as it may seem, I myself was born in 1964, and will also turn 60 next year. At this juncture, I hope that we can give thought to the future of nuclear medicine and the JSNM, and hold lively discussions when we gather in Yokohama. I look forward to seeing you in the crisp fall air of that lovely port city.

Congress Secretariat

c/o Congrès Inc
Onward Park Building, 3-10-5
Nihonbashi, Chuo-ku, Tokyo
103-8276, Japan
E-mail: jsnm-jsnmt2024@congre.co.jp